Your session is about to expire
← Back to Search
Cohort 3 for Bloodstream Infection
Study Summary
This trial is testing a new drug to see if it is safe and effective. It is given to healthy participants to test the safety, tolerability, and how the body processes the drug.
- Bloodstream Infection
- E. coli Infections
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment presently available for this clinical study?
"According to clinicaltrials.gov, the recruitment process for this trial, which was initially posted on March 24th 2022 and last modified on December 1st 2022, is now concluded. Nevertheless, there are 911 other medical studies currently enrolling participants across the globe right now."
Does this research endeavor accept participants who are above the age of sixty?
"This study seeks individuals aged 18 and above, yet still under 65."
Has the regulatory body approved Cohort 1 for commercial use?
"The safety of Cohort 1 has been estimated with a score of one due to the fact that this is an early-stage trial. Thus, there is limited evidence regarding its efficacy and safety."
What type of volunteers is this research endeavor calling for?
"Candidates aged between 18 and 65 with escherichia coli infections are eligible to enroll in this clinical trial. Currently, the team is hoping to recruit 36 participants."
Share this study with friends
Copy Link
Messenger